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Abstract: Rates of adverse cardiovascular events have increased among middle-aged adults.
Elevated ceramides have been proposed as a risk factor for cardiovascular events. Diet quality and
weight status are inversely associated with several traditional risk factors; however, the relationship
to ceramides is less clear. This study aimed to determine associations of adiposity and diet quality
with circulating ceramides in middle-aged adults (n = 96). Diet quality was estimated using the
Healthy Eating Index 2015 (HEI-2015). Serum ceramide concentrations were determined by liquid
chromatography–mass spectrometry. A ceramide risk score was determined based on ceramides
C16:0, C18:0, and C24:1 and their ratios to C24:0. Participants who were classified as at ‘moderate risk’
compared to ‘lower-risk’ based on a ceramide risk score had significantly higher body mass index
(BMI) values, as well as higher rates of elevated fibrinogen levels, metabolic syndrome, and former
smoking status. BMI was positively associated with the ceramide C18:0 (R2 = 0.31, p < 0.0001),
the ratio between C18:0/C24:0 ceramides (R2 = 0.30, p < 0.0001), and the ceramide risk score (R2 = 0.11,
p < 0.009). Total HEI-2015 scores (R2 = 0.42, p = 0.02), higher intakes of vegetables (R2 = 0.44, p = 0.02)
and whole grains (R2 = 0.43, p = 0.03), and lower intakes of saturated fats (R2 = 0.43, p = 0.04) and
added sugar (R2 = 0.44, p = 0.01) were associated with lower C22:0 values. These findings suggest
that circulating ceramides are more strongly related to adiposity than overall diet quality. Studies are
needed to determine if improvements in weight status result in lower ceramides and ceramide
risk scores.
Keywords: diet quality; ceramides; obesity; cardiovascular risk; healthy eating index
1. Introduction
Cardiovascular disease (CVD) and major CVD events such as myocardial infarction (MI) and
stroke are largely preventable, yet they remain leading causes of death, disability, and health care
spending in the United States (U.S.) [1]. In 2016, a third of all MIs and strokes in the U.S. occurred in 35
to 64-year-old adults [1]. As a result, CVD mortality rates are increasing in middle-aged adults despite
declines in the general population over the past few decades [2]. Prevention efforts focus on identifying
and treating modifiable risk factors such as dyslipidemia, diabetes, hypertension, and obesity [2].
However, traditional risk factors are not always strong predictors of events. Many patients hospitalized
for an MI or stroke have low-density lipoprotein (LDL) levels within a normal range [3], suggesting
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that those at CVD risk are not being identified before the disease progresses to an event. There is
emerging evidence that a class of lipids—ceramides—may play an important role in the pathogenesis
of CVD, and may better predict CVD events than some traditional risk factors [4–6].
Ceramides are a bioactive class of lipids that are synthesized via several molecular pathways,
of which the most characterized is de novo synthesis. De novo synthesis begins with palmitoyl
CoA and the amino acid l-serine. Then, the resulting sphingoid base is attached to fatty acid side
chains of different lengths and degrees of unsaturation, leading to a group of molecules [7] that are
diverse in structure and function [8,9]. Ceramides play a role in cell membrane integrity, inflammation,
and apoptosis [10], and when they accumulate, they are thought to contribute to the progression of
chronic disease, including atherosclerosis [11]. Their low levels in biological samples, large biodiversity,
and polar nature made it difficult to quantify ceramides [7]. However, recent advances in mass
spectroscopy now allow for the quantification of these small-molecule metabolites, some of which may
be prognostic markers for CVD [12].
Elevated circulating concentrations of three specific ceramides: N-palmitoyl-sphingosine
(C16:0), N-stearoyl-sphingosine (C18:0), and N-nervonoyl-sphingosine (C24:1) were found to be
predictive of CVD events in patients with coronary artery disease independent of traditional risk
factors [4]. The predictive value was found to be greater when the ceramides were normalized to
N-lignoceroyl-sphingosine (C24:0), which is a ceramide that is abundant in the circulation but thought
not to be related to CVD [4]. In 2016, the Mayo Clinic began offering a diagnostic test to measure
ceramides and assign the risk of a future CVD event based on a ceramide risk score. The risk score is
based on six values: C16:0, C18:0, and C24:1, and the ratio of each to C24:0 [5]. Participants classified
at higher risk based on their ceramide risk score were four times more likely to suffer a CVD event
than those at lower risk [4] independent of age, sex, smoking status, and LDL cholesterol [4,5].
Evidence-based clinical care guidelines for reducing elevated ceramide levels and the risk score
are not available [13]. It has been suggested that changes in diet may help lower ceramides, and thus
CVD risk; however, controlled studies have not been conducted in humans. Higher diet quality and
adherence to healthy dietary patterns have been associated with lower CVD risk and mortality [14].
However, no studies have assessed the relationship of diet quality or adherence to United States (U.S.)
Dietary Guidelines for Americans (DGAs) as measured by the Healthy Eating Index 2015 (HEI-2015)
on circulating ceramides or the ceramide risk score. It is plausible that interventions effective in
reducing traditional risk factors also modify circulating ceramides. Studies have shown that circulating
ceramides can be modified through exercise [15], statin use [16,17], and weight loss post-bariatric
surgery [18,19]. Short-term intervention studies in small samples of healthy humans have shown that
caloric excess and increased saturated fat intake increase ceramide levels [20–22]. However, there were
no significant changes in ceramides after one year in participants at high CVD risk in the PREDIMED
(Prevention with Mediterranean Diet) study [23].
The relationship between adiposity, diet quality, and ceramides that make up the ceramide risk
score is largely unknown. In the U.S., people living in the state of West Virginia experience higher
rates of obesity, type 2 diabetes, and hypertension [24], and lower rates of adequate fruit and vegetable
intake [25] than any other state in the nation. CVD risk reduction is a public health priority in the state.
Middle-aged adults represent a priority population in national health campaigns. The purpose of this
study was to determine if diet quality (e.g., adherence to the U.S DGAs), and adiposity were associated
with serum ceramides and the ceramide risk score in middle-aged West Virginians with at least one
risk factor for CVD.
2. Materials and Methods
2.1. Study Design and Sample
In this cross-sectional study, data were analyzed from 96 middle-aged adults (45 to 64 years old)
who took part in a larger diet and cardiovascular risk assessment study. Participants were recruited
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from two counties in north-central West Virginia by word-of-mouth and community advertising.
Exclusion criteria included current smokers; diagnosis of cancer or kidney, heart, or liver disease;
surgery six months prior; and anti-inflammatory or anticoagulant medications.
The study consisted of three modes of data collection: multiple telephone interviews to assess
dietary intake; an online survey administered using REDCap (Research Electronic Data Capture),
which is a secure web-based application designed to support data capture for research studies [26];
and an in-person health assessment. At the in-person health assessment, anthropometric and blood
pressure measurements were taken by research staff, and a trained phlebotomist performed a fasting
venous blood draw. The study protocol was approved by the West Virginia University (WVU)
Institutional Review Board. All the participants provided informed consent before participation and
received a $100 gift card upon completion of the study.
2.2. Demographic and Health-Related Data
Demographic data and smoking history were self-reported via the online survey. Participants also
provided health and medication history at the in-person visit. Blood collected was analyzed by WVU
Hospital lab for LDL cholesterol, high-density lipoprotein (HDL) cholesterol, non-HDL cholesterol,
triglycerides, glucose, insulin, C-reactive protein (CRP), and fibrinogen. Insulin sensitivity was
calculated using the homeostatic model assessment of insulin resistance (HOMA-IR) as fasting insulin
(mU L−1) × fasting glucose (mmol L−1)/22.5 [27] using measured fasting glucose and insulin values.
Participants were classified as having a health condition if at least one of the following criteria was met:
(1) they reported being diagnosed by a health care provider, (2) they reported taking a medication that
is used to treat the condition, or (3) the measured laboratory values or blood pressure (BP) met standard
diagnostic cut-off values. The cut-off values for the diagnoses were as follows: pre-diabetes or diabetes,
fasting plasma glucose >100 mg/dL [28]; dyslipidemia, LDL ≥100 mg/dL or triglycerides ≥150 mg/dL;
hypertension, systolic BP >120 or diastolic BP >80 mm Hg [29]; and a diagnoses of metabolic syndrome
required meeting three of the 5 factors defined by the National Cholesterol Education Program Adult
Treatment Panel III [30].
Blood pressure was measured using the Omron HEM-907XL Intellisense® Automatic Oscillatory
Digital Blood Pressure monitor (Omron Health Care, Lake Forest, IL, USA) [31]. A single assessor
performed all the blood pressure measurements. Arm circumference was measured to the nearest 0.1 cm
to determine appropriate cuff size based on manufacturer recommendations. With the participant
in a seated upright position and after an initial rest of 5 min, the machine took three blood pressure
measurements at 30-second intervals; the average reading was used for analysis [32]. Anthropometric
and body composition measurements were taken using standardized protocols, with participants
fasted, lightly clothed, and without shoes. Measurements were recorded in duplicate, and averages
were used for analysis. Height (cm) was measured using the Seca 274 digital mobile stadiometer (Seca,
Hamburg, Germany). Weight (kg) and fat mass index (FMI) (kg/m2) were measured using the Seca
medical Bioelectrical Composition Analyzer (mBCA) 514 (Seca, Hamburg, Germany). Body mass index
(BMI) was calculated as weight (kg)/height (m2) and was classified using World Health Organization
classifications [33]. Waist and hip circumferences (cm) were measured using a Gulick II Tape Measure.
Waist circumference (WC) was measured at the iliac crest; values >102 cm for men and >88 cm for
women were classified ‘at risk’ [33]. Hip circumference was measured at the maximum point of
protuberance of the buttocks. Waist–hip ratio (WHR) was calculated as waist circumference (cm)/hip
circumference (cm); values were classified as ‘at risk’ if WHR was ≥0.90 cm for men and ≥0.85 cm for
women [33].
2.3. Diet Quality Assessment
Dietary intake data were collected and analyzed using three 24-hour dietary recalls and
Nutrition Data Systems for Research (NDSR) software version 15 (2015) developed by the Nutrition
Coordinating Center, University of Minnesota, Minneapolis, MN. Self-reported dietary intake was
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obtained via telephone interview by trained research personnel using the NDSR four-pass method on
non-consecutive days (one weekend and two weekdays). Food and nutrient data was transformed into
the HEI-2015 metric, which measures adherence to the 2015–2020 Dietary Guidelines for Americans
(DGAs) [34] based on 13 components (nine adequacies and four moderation). To calculate the HEI-2015
scores, NDSR output data was transformed into HEI component variables using NDSR’s unpublished
guide [35]. Food group servings (total fruits, whole fruits, total vegetables, greens and beans, whole
grains, dairy, total protein foods, seafood and plant proteins, and refined grains) were converted to total
servings per 1000 kilocalories and sodium intake was converted to mg per 1000 kilocalories. A ratio
of polyunsaturated fatty acids (PUFAs) and monounsaturated fatty acids (MUFAs) to saturated fatty
acids (SFAs) was generated by dividing the sum of PUFAs and MUFAs by SFAs. Added sugars and
saturated fats were assessed as percent of kilocalories. For the four moderation components—refined
grains, sodium, added sugars, and saturated fats—higher scores represent lower intakes. Once the
NDSR components were in units consistent with the HEI metric, the simple HEI scoring algorithm
method for multiple days of intake data was applied [36]. Component scores were summed for a total
score ranging from 0–100, with higher scores indicating better adherence to the 2015–2020 U.S. DGAs.
2.4. Ceramides Analysis
Lipidomics analysis was conducted by the WVU Metabolomics Core using liquid
chromatography–mass spectrometry (LC-MS). Serum samples were extracted using a modified Bligh
and Dyer procedure using C12:0-ceramide as an internal standard (Avanti Polar Lipids, Alabaster, AL,
USA) using previously described methods [37,38]. Following liquid–liquid extraction, the organic layer
was dried under nitrogen gas (Organomation Associates Inc., Berlin, MA, USA) and resuspended in
pure methanol before analysis. Ceramides were separated by gradient elution using ultra high-pressure
liquid chromatography (ExionLC AD, SCIEX, Framingham, MA, USA) on a C18 reverse-phase column
(Phenomenex, Torrence, CA, USA). Ceramides were detected using electrospray ionization tandem
mass spectrometry (ESI-MS/MS) as previously described (QTRAP 5500, SCIEX) [39]. Ionspray source
voltage was 5000 V at a temperature of 500 ◦C. Nebulizer, heater, curtain, and collision gas pressures
were maintained at 70, 60, 28, and 9 psi, respectively. Ceramide ionization parameters were optimized
individually, ranging from a declustering potential of 30 to 50 V, an entrance potential of 10 to 15 V,
collision energy of 32 to 37 V, and a collision cell exit potential of 13 to 17 V. Ceramides were measured
by multiple reaction monitoring of the protonated molecular ion with a transition ion of 264.2 m/z.
Eleven-point calibration curves (0.1 ng/mL to 10 µg/mL) were constructed by plotting the area under
the curve for C16:0-ceramide, C18:0-ceramide, C22:0-ceramide, and C24:0-ceramide (Avanti Polar
Lipids). Fluctuations in extraction and ionization efficiencies were controlled by normalizing to the
C12:0-ceramide response, and samples were re-run if the internal standard response deviated more
than 20% from its median value. Concentrations were determined by curve fitting the identified
ceramide species based on acyl-chain length. Standards were injected in duplicate to ensure similar
response (the overall mean CV was 12.08%; R2 ≥ 0.985). Instrument control and quantitation were
performed using Analyst 1.6.3 and MultiQuant 3.0.2 software, respectively (SCIEX).
2.5. Ceramides Risk Score
The ceramides used in this analysis included the six variables that make up the ceramide risk score
(C16:0, C18:0, C24:1, C16:0/C24:0, C18:0/C24:0, and C24:1/C24:0) [40] and two additional ceramides
(C20:0 and C22:0) that were identified in the literature as being related to diet [20,41], adiposity [42],
or CVD risk [15,23,43]. Ceramides (ng/mL) were converted to units that were consistent with the
ceramide risk score (µmol/L). Ceramide risk scores were calculated by assigning a value between 0–2
to each of the six risk score components based on published cut-off values [4,5]. The six component
scores were summed for a total ceramide risk score ranging from 0 to 12, with higher scores indicating
a higher risk of adverse cardiovascular events. The scores were categorized into risk groups: lower
risk (0–2), moderate risk (3–6), and increased risk (7–9) [4]. No participant scores met a fourth category:
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higher risk (10–12). For analysis purposes in this study, the ‘increased risk’ category was combined
into the ‘moderate risk’, as only three participants had scores in the increased risk category.
2.6. Statistical Analysis
Demographic and health-related data were reported as means and standard errors of the mean
(SEM) or frequency with percentage, when appropriate. Ceramides and risk factors for CVD (i.e.,
cholesterol, triglycerides, glucose) were log-transformed to achieve a normal distribution for analysis.
Medians and interquartile ranges were reported for non-normally distributed variables. To assess
differences between ceramide risk score categories for all the demographic and clinical characteristics,
Student’s t-test or Chi-square tests were performed when appropriate. Bivariate analysis was performed
to assess the relationship between potential confounding variables (demographics, health conditions,
CVD biomarkers, inflammatory markers, and lifestyle factors) and each ceramide and the ceramide
risk score. The Benjamini–Hochberg procedure was performed to control for excessive Type I error due
to multiple analyses, with a false discovery rate set to 10%. The variables that remained significant after
the Benjamini–Hochberg procedure were entered into a stepwise regression model, with alpha-to-enter
set at 0.15 and alpha-to-remove set at 0.15. This enabled us to estimate the effect of multiple variables
on ceramides and the ceramide risk score. The variables that remained significant were included in the
adjusted model. Multiple linear regression models were done to assess the hypothesized relationship
between the HEI-2015 diet quality score and BMI on a continuous scale with individual ceramides
along with the ceramide risk score. These models enabled us to assess if the HEI-2015 or BMI were
associated with ceramide levels when adjusted for other significant clinical, demographic, or lifestyle
characteristics. The 13 HEI-2015 components were analyzed further using multiple linear regression
models with individual ceramides and the ceramide risk score. BMI was further analyzed categorically
against each individual ceramide and the ceramide risk score using one-way ANOVA and Tukey’s HSD
(honestly significant difference) test for comparison of BMI categories (normal, overweight, and obese).
All data analyses were performed using JMP and SAS software (JMP®, Version Pro 12.2,
SAS Institute Inc., Cary, NC, USA, Copyright©2015; SAS®, Version 9.4, SAS Institute Inc., Cary, NC,
USA, Copyright©2002–2012). Power of the test was determined as 80% for the relationship of BMI
and the ceramide risk score. Significance criterion alpha for all tests was 0.05.
3. Results
3.1. Participant Characteristics by Ceramide Risk Category
Overall, most participants were non-Hispanic white (95.8%), college educated (57.3%), and had
annual household incomes >$50,000 (67.4%). Demographic and health-related characteristics by
ceramide risk category are presented in Table 1. The mean age of the sample was 54 ± 4.7 years
old Over half were women (57.3%). The mean BMI was 30.85 ± 7.23; 51.1% were classified as obese.
All the participants had at least one cardiovascular risk factor; 92% had dyslipidemia (controlled and
uncontrolled). Participants classified at ‘moderate risk’ compared to ‘low-risk’ based on ceramide
risk category had significantly higher BMI (p = 0.003), WC (p = 0.005), and FMI (p = 0.004), elevated
fibrinogen levels (35.0% versus 14.3%, p = 0.02), higher rates of metabolic syndrome (52.5% versus
28.6%, p = 0.02), and had formerly smoked (62.5% versus 1.1%, p = 0.04).
The most abundant circulating ceramides were C24:0 followed by C22:0 and C24:1. Ceramide risk
scores ranged from 0 to 8 out of a possible 12 points; 58.3% were in the low-risk group, and 41.7% were
in the moderate risk or increased risk groups. Supplemental Table S1 shows quantities of ceramides by
risk category.
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Table 1. Participant characteristics by ceramide risk category.
All
N = 96
Lower Risk 1
n = 56
Moderate Risk 2
n = 40 p-Value
3
Demographic Factors
Age, year 54.30 ± 0.47 53.95 ± 0.55 54.8 ± 0.84 0.40
Sex, women 55 (57.3%) 33 (58.9%) 22 (55.0%) 0.70
Health-Related Factors
Adiposity
Body Mass Index, kg/m2 30.85 ± 0.74 29.22 ± 0.92 33.13 ± 1.13 0.003
Waist Circumference, cm 103.35 ± 1.67 99.41 ± 2.07 108.87 ± 2.55 0.005
Elevated Waist Circumference 4 70 (72.9%) 37 (66.1%) 33 (82.5%) 0.07
Waist-to-Hip Ratio, cm 0.90 ± 0.008 0.89 ± 0.01 0.91 ± 0.01 0.16
Elevated Waist-to-Hip Ratio 5 63 (65.6%) 36 (64.3%) 27 (67.5%) 0.74
Fat Mass Index, kg/m2 12.26 ± 0.55 11.00 ± 0.65 14.02 ± 0.89 0.004
Laboratory Values
Total Cholesterol ≥200 mg/dL 52 (54.2%) 30 (53.6%) 22 (55.0%) 0.89
LDL ≥100 mg/dL 77 (81.1%) 43 (76.8%) 34 (87.2%) 0.20
Low HDL 6 22 (22.9%) 12 (21.4%) 10 (25.0%) 0.68
Triglycerides ≥150 mg/dL 18 (18.8%) 9 (16.1%) 9 (22.5%) 0.43
Glucose >100 mg/dL 35 (36.5%) 19 (33.9%) 16 (40.0%) 0.54
Insulin >24 mg/dL 4 (4.17%) 1 (1.8%) 3 (7.5%) 0.17
HOMA-IR 2.18 ± (0.17) 1.97 (0.19) 2.48 (0.31) 0.19
CRP ≥8 mg/dL 16 (16.7%) 9 (16.1%) 7 (17.5%) 0.85
Fibrinogen >400 mg/dL 22 (22.9%) 8 (14.3%) 14 (35.0%) 0.02
Medical Conditions
Metabolic Syndrome 37 (38.5%) 16 (28.6%) 21 (52.5%) 0.02
Diabetes 39 (40.6%) 22 (39.3%) 17 (42.5%) 0.75
Dyslipidemia 88 (91.7%) 50 (89.3%) 38 (95.0%) 0.32
Hypertension 37 (38.5%) 18 (32.1%) 19 (47.5%) 0.13
Statin use 23 (24.0%) 13 (23.2%) 10 (25.0%) 0.84
Lifestyle Factors
Former Smoker 48 (50.0%) 23 (41.1%) 25 (62.5%) 0.04
HEI-2015 Diet Scores 54.05 ± 1.45 55.27 ± 1.73 52.36 ± 2.49 0.34
Values are means ± SEM for continuous variables or n (%) for categorical variables. Abbreviations: LDL, low-density
lipoprotein; HDL, high-density lipoprotein; HOMA-IR, homeostatic model assessment of insulin resistance; CRP,
C-reactive protein; HEI-2015, Healthy Eating Index 2015. 1 Lower risk: ceramide risk score 0–2. 2 Moderate risk:
ceramide risk score 3–6, and three participants with scores of 7 (n = 2) and 8 (n = 1). 3 Student’s t-test or chi-square
tests were used to test significance; significant p-value <0.05. 4 Elevated waist circumference is >102 cm for men
and >88 cm for women. 5 Elevated waist-to-hip ratio is ≥0.90 cm for men and ≥0.85 cm for women. 6 Low HDL is
<40 mg/dL for men and <50 mg/dL for women.
3.2. Relationship between Potential Covariates and Ceramide
Age, gender, income, statin use, and hypertension were not significantly associated with any of the
ceramides or the risk score. All of the adiposity measures (i.e., WC, WHR, and FMI); several laboratory
values (LDL, HDL, non-HDL, triglycerides, glucose, insulin, HOMA-IR, fibrinogen, and CRP); having
a diagnosis of diabetes or metabolic syndrome, and being a former smoker were each significantly
associated with at least one ceramide or the risk score. However, after stepwise regression, only LDL,
HDL, non-HDL, glucose, FMI, fibrinogen, and smoking status remained significantly associated with
individual ceramides or the risk score, and therefore were the only covariates included in the adjusted
models. Supplemental Table S2 depicts the results of bivariate analyses of associations between
traditional CVD risk factors and ceramides.
3.3. Relationship of BMI (Adiposity) and HEI (Diet Quality) with Ceramides
Table 2 shows the associations between BMI and HEI scores with ceramides. BMI was associated
with C18:0, C16:0/24:0, C18:0/C24:0, and the ceramide risk score in unadjusted models, and remained
positively associated with C18:0, C18:0/C24:0, and the ceramide risk score after adjusting for covariates.
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The diet quality scores measured by HEI-2015 ranged from 25.6 to 87.7 out of 100 points. The mean
score was 54.05 ± 1.45, indicating ‘needing improvement’ (HEI scores 51–80). Diet quality was inversely
associated with only one ceramide, C22:0, in both unadjusted and adjusted models. It was not associated
with any of the ceramides that make up the risk score. Ceramides C16:0, C24:0, and C24:1/24:0 were
not associated with any of the outcome variables.
Table 2. Associations between BMI (adiposity) and HEI-2015 (diet quality) with ceramides.
Outcome Variables
Ceramides Included in the Ceramide Risk Score Ceramide
Risk Score
Other Ceramides
C18:0 C24:1 C16:0/24:0 C18:0/24:0 C20:0 C22:0
Unadjusted Model
BMI (kg/m2)
0.80; 0.19
(<0.001) NS
0.36; 0.07
(0.006)
1.02; 0.26
(<0.001)
5.97; 0.07
(0.006) NS NS
HEI-2015 NS NS NS NS NS NS −0.002; 0.06(0.009)
Adjusted Models
BMI (kg/m2)
0.81; 0.31
(<0.0001) NS NS
0.91; 0.30
(<0.0001)
5.58; 0.11
(0.009) NS NS
HEI-2015 NS NS NS NS NS NS −0.002; 0.42(0.02)
Values reported are slope per unit change; coefficient of determination R2 and (significant p-value). Abbreviations:
HEI-2015, Healthy Eating Index 2015; BMI, body mass index; NS, not significant. Covariates used in adjusted models
varied by ceramide: C18:0 (HDL-C, glucose); C24:1 (LDL, non-HDL); C16:0/24:0 (glucose, fibrinogen); C18:0/24:0
(glucose); C24:1/24:0 (smoking); ceramide risk score (smoking); C20:0 (LDL, non-HDL); C22:0 (LDL, non-HDL).
Table 3 depicts the associations between individual HEI-2015 component scores and ceramides.
After adjusting for confounding risk factors, HEI scores that represent the recommended intakes for
total vegetables, whole grains, saturated fats, and added sugars were each inversely associated with
C22:0. That is, higher intakes of vegetables and whole grains and lower intakes of saturated fats and
added sugar were associated with lower C22:0 values. Absolute saturated fat intake (grams per day)
was significantly and positively associated with C22:0 (R2 = 0.41, p = 0.04). Individual HEI components
(i.e., whole fruit, total fruit, greens and beans, dairy, total protein foods, seafood and plant protein,
unsaturated to saturated fatty acid ratio, and sodium) were not associated with any ceramides or the
ceramide risk score.
Table 3. Associations between the Healthy Eating Index (HEI-2015) components and ceramides.
HEI Component
Ceramides in Risk Score Other Ceramides
C16:0 C24:1 C16:0/24:0 C20:0 C22:0
Unadjusted Models
Total Vegetables −0.02; 0.04 (0.02) NS NS NS −0.03; 0.05 (0.01)
Whole Grains NS NS NS −0.01; 0.04 (0.03) −0.01; 0.04 (0.03)
Refined Grains NS NS −0.007; 0.04 (0.03) NS NS
Saturated Fats NS −0.01; 0.05 (0.01) NS −0.02; 0.06 (0.01) −0.02; 0.08 (0.003)
Added Sugar NS NS NS NS −0.01; 0.07 (0.007)
Adjusted Models
Total Vegetables NS NS NS NS −0.02; 0.44 (0.02)
Whole Grains NS NS NS NS −0.007; 0.43 (0.03)
Saturated Fats NS NS NS NS −0.008; 0.43 (0.03)
Added Sugar NS NS NS NS −0.009; 0.44 (0.01)
Values reported are slope per unit change; coefficient of determination R2 and (p-value). Abbreviations: HEI-2015,
Healthy Eating Index 2015; NS, not significant. Ceramides not significant with any HEI-2015 components were
C18:0, C24:0, C18:0/24:0, C24:1/C24:0 or the ceramide risk score (not shown). Covariates used in adjusted models
varied by ceramide: C16:0 (HDL, non-HDL, glucose); C24:1 (LDL, non-HDL); C16:0/24:0 (glucose, fibrinogen); C20:0
(LDL, non-HDL); C22:0 (LDL, non-HDL). Significant p-value <0.05.
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Figure 1 depicts ceramide concentrations by BMI category. Of the 96 participants, 22.9% were
classified as normal weight, 26.0% were classified as overweight, and 51.0% were classified as obese.
Five of the six values that make up the ceramide risk score (C16:0, C18:0, C16:0/24:0, C18:0/24:0,
C24:1/24:0, and C20:0) were all significantly higher in participants classified as obese compared to
normal weight. Four of the six values in the risk score (C16:0, C18:0, C16:0/24:0, and C18:0/24:0) were
significantly higher in participants classified as overweight compared to normal weight. Figure 2
shows the ceramide risk score by BMI category. The risk score increased by BMI category and was
significantly higher between participants classified as normal weight versus obese (1.36 ± 0.24 versus
3.14 ± 0.31, p = 0.001).
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Figure 1. (A) Serum ceramide concentrations (µmol/L) by BMI category: normal weight
(18.5–24.9 kg/m2), overweight (25–29.9 kg/m2), and obese (≥30 kg/m2). Values reported are mean
concentrations. (B) Cerami e ratios included in the risk score by BMI c tegory. Values are means of
ratios. Tukey’s honestly significant difference (HSD) was used to test significance between the three
BMI categories. * Significant p-values < 0.05.
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4. Discussion
This is the first study to examine the cross-sectional associations of adiposity and diet quality
with the ceramide risk score, which is an emerging risk factor for CVD. We detected that even between
the two lowest ceramide risk score categories, there were significant differences between groups for
adiposity (BMI and FMI), and rates of elevated fibrinogen (a proinflammatory mediator), metabolic
syndrome, and former smoker status. BMI was positively associated with the ceramide risk score
and two of the six ceramide values in the risk score (C18:0 and C18:0/24:0). Total HEI-2015 scores and
four diet component scores (total vegetables, whole grains, saturated fats, and added sugars) were
inversely associated with only one ceramide, C22:0, which is a ceramide associated in the literature
with diet [20,41] but not included in the ceramide risk score. Higher diet component scores indicate
improvements in diet quality. That is, higher scores represent higher intakes of vegetables and whole
grains, but lower intakes of saturated fats and added sugar.
Similar to other studies, the most abundant serum ceramides were C24:0 and C24:1 [44,45].
Ceramide C24:0 was positively associated with LDL, non-HDL, and triglycerides, as has been reported
in other studies [4], but inversely associated with fibrinogen in our population. We did not see
associations between statin use and ceramides. Study results have been inconsistent, with some studies
showing lower circulating ceramides in participants taking statins [42,46] and others such as ours, did
not [42]. In our population, 91.7% of participants had dyslipidemia. However, 24% reported statin
use, but of those, 60.9% still had high lipid levels, suggesting that the statins were ineffective or that
participants were not regularly taking their medications. Additionally, significantly more participants
with metabolic syndrome were in the moderate ceramide risk category compared to the low-risk
category. This finding is consistent with other studies that ceramides may be inducers of metabolic
disorders [47].
4.1. Associations between Adiposity and Ceramides
BMI was positively associated with the ceramide risk score, C18:0, and C18:0/24:0 after adjusting
for confounding variables. To our knowledge, no other studies have compared BMI with this
specific total ceramide risk score, but studies have reporte an association between BMI and various
circulating ceramide species. Circ lating C18:0 was associated with BMI in several studies [4,42,44].
Consistent with our study, Meeusen et al. reported an association between BMI and two of the six
risk components of the risk score (C18:0 and C18:0/C24:0); however, the association as minimal
(R2 value <3%) compared to the 30% in this study [4]. Differences in populations and overall sample
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size (n = 495 versus n = 96) may account for variation in the strength of the associations. In contrast,
Mielke et al. reported additional associations of BMI with C16:0, C24:1, C20:0, and C22:0 among
middle-aged subjects with an average BMI of 26 kg/m2 (overweight) [42] that we did not detect. In a
small sample, Haus et al. detected higher concentrations of C18:0, C20:0, and C24:1 ceramides in
subjects with type 2 diabetes and obesity (n = 13) compared to lean healthy control subjects (n = 14) [44].
A possible mechanism for increased serum ceramides is that in obese humans, circulating free fatty
acids, which serve as substrates for ceramide synthesis via the de novo pathway, are elevated, leading
to an overproduction of ceramides [48,49]. Ceramides can be synthesized in several different tissues,
but those synthesized in the liver can be readily incorporated in very low-density lipoprotein (VLDL)
particles and released into the circulation [50]. Ceramides circulate in the blood mainly associated with
lipoprotein particles, VLDL and LDL [50]. Thus, overproduction in the liver is a potential source for
elevated circulating ceramides. Excess ceramides are postulated to be the mechanistic link between
obesity and obesity-related chronic conditions. Thus, our research adds to literature suggesting a link
between obesity and a potential overproduction and accumulation of C18:0 species and the overall
ceramide risk score. Studies are needed that determine if dietary interventions for weight loss result in
a reduction of the ceramides in the risk score.
4.2. Associations between Diet Quality and Ceramides
We did not detect associations between diet quality and ceramide species in individual ceramides
in the risk score or total risk score; however, greater HEI scores were associated with lower C22:0
concentrations after adjusting for LDL and non-HDL cholesterol. We found that 42% of the variation
in C22:0—a very-long-chain ceramide with a saturated acyl chain—was explained by the HEI scores
indicating a strong association. There is limited research on the associations between diet and ceramides.
This was the first study to assess the relationship between the a priori HEI metric of diet quality and
ceramides as a marker for CVD risk. However, other studies have shown that the HEI score was related
to reductions in other CVD risk factors such as LDL [51] and reductions in CVD mortality [14,52].
While C22:0 is not part of the ceramide risk score, previous studies showed that it is positively
associated with CVD risk in humans [23,43]. Two intervention studies that measured C22:0 found
that it was modifiable by diet [20,41]. One intervention of 200 subjects who were between 30–65 years
old with metabolic syndrome aimed to determine how a Nordic diet affected the lipidomic profile
compared to control subjects. Subjects in the intervention consumed a dietary pattern of higher
amounts of fiber, vegetables, fruits, berries, and fish, lower intakes of salt and sugar, and a higher
quality of dietary fat than the control for 18 to 24 weeks. The control group received low-fiber cereal
products and dairy fat such as butter [41]. Results indicated a significant decrease in C22:0, C23:0,
and C24:0 concentrations compared to the control group after 12 weeks, but not after 24 weeks [41].
In another study, Heilbronn et al. also observed an elevation in C22:0 by 25% in subjects overfed by
1250 kilocalories per day for 28 days [20].
When assessing individual HEI components, we found that participants had higher scores,
indicating that better adherence to recommendations for saturated fat intake (≤8% of energy intake)
had lower C22:0 concentrations. Additionally, participants who consumed higher amounts of absolute
saturated fat (grams per day) had higher C22:0. De novo ceramide synthesis depends on the availability
of free fatty acids, specifically the saturated fat palmitate [10]. The overconsumption of this saturated
fat may result in excess ceramide accumulation [10]. Additionally, in our population, better adherence
to the DGAs for total vegetable intake, whole grain intake, and added sugar intake was also associated
with lower C22:0. This suggests that multiple components of the diet work synergistically, and that
dietary patterns should be studied in relationship to ceramides in larger samples. Future studies on
the relationship between ceramides and diet quality are needed, specifically long-term intervention
studies to assess changes in ceramides after improvements in diet quality.
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4.3. Limitations
There are several limitations to this study. First, our sample size was small and used a convenience
sample whose ceramide risk scores fell largely within the two lowest groups of risk. A larger sample
may have included a broader range of risk scores, and associations may have been detected when the
lowest versus highest scores are compared. Second, the majority of participants were non-Hispanic
white, which is representative of the population in West Virginia, but makes it difficult to generalize
findings to other populations. Third, the cross-sectional study design does not allow for cause–effect
relationships. Studies are needed to investigate long-term changes in ceramides over time. Lastly,
the study used self-reported data, such as dietary intake, medications, and medical conditions. There are
inherent limitations with self-reported intake data, specifically the under-reporting of dietary intake or
failing to report all the medications used.
4.4. Clinical implications
Laboratory tests are currently available that quantify ceramides and categorize risk of CVD
events.. However, studies have not yet been conducted to inform evidence-based guidelines on
treatments to effectively modify ceramides should they be elevated. It is plausible that diet, lifestyle,
and lipid-lowering medications known to reduce traditional risk factors may also be effective in
lowering ceramides. Large epidemiological studies to confirm the relationship between specific
ceramides and CVD events, and interventional studies to determine the effectiveness of treatment
strategies in reducing ceramides and CVD events are urgently needed. Until this data is available, it
seems premature to use ceramides as a therapeutic target in clinical practice.
5. Conclusions
This study showed that middle-aged adults with obesity had higher circulating C18:0 and
C18:0/24:0, and higher ceramide risk scores than those who were normal weight or overweight.
Higher BMI remained independently associated with higher ceramide levels after adjusting for
confounding variables. Future studies are needed to determine if a reduction in weight status results in
lower ceramide risk scores in humans, and if interventions to improve diet quality would be effective
in lowering ceramides and the ceramide risk score.
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